Tag: MRA
-
Finerenone’s commercial moat (Part 3): “the only nonsteroidal MRA with hard-outcome trials” — a real but time-limited advantage boxed in on three sides
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment or medical advice. The 30-second version What. Finerenone (Bayer’s Kerendia) is currently the only nonsteroidal MRA (nsMRA) with hard-outcome RCT evidence. That single fact is its commercial moat: every competitor is on a surrogate…
-
The finerenone landscape — a nonsteroidal MRA as the third pillar of CKM care, and what is still an open question
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice, not medical advice. The 30-second version What. Finerenone is a nonsteroidal mineralocorticoid receptor antagonist (MRA) that targets inflammation and fibrosis rather than blood pressure and volume — a mechanism that does not overlap…
Uthando Nethemba 